Kaiser Permanente Vaccine Study Center: Highlights of 2009-2012

Overview

Journal Vaccines (Basel)

Date 2015 Sep 8

PMID 26343963

Authors

Roger Baxter

Nicola P Klein

Affiliations

Soon will be listed here.

Abstract

The Kaiser Permanente Vaccine Study Center is a specialized research organization in Oakland, California. They have been an active vaccine research group for many years, and have participated in and led a multitude of vaccine studies. This article will review the last three years of research activities.

References

Blatter M, Klein N, Shepard J, Leonardi M, Shapiro S, Schear M . Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012; 31(8):e133-40. DOI: 10.1097/INF.0b013e318259fc8a. View

Baxter R, Ray G, Fireman B . Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine. 2010; 28(45):7267-72. DOI: 10.1016/j.vaccine.2010.08.088. View

Klein N, Hansen J, Lewis E, Lyon L, Nguyen B, Black S . Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010; 29(7):613-7. DOI: 10.1097/INF.0b013e3181d581f9. View

Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen S . Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013; 167(12):1111-7. DOI: 10.1001/jamapediatrics.2013.2745. View

Klein N, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R . Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012; 367(11):1012-9. DOI: 10.1056/NEJMoa1200850. View

Reisinger K, Baxter R, Block S, Shah J, Bedell L, Dull P . Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009; 16(12):1810-5. PMC: 2786376. DOI: 10.1128/CVI.00207-09. View

Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T . The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011; 127 Suppl 1:S45-53. DOI: 10.1542/peds.2010-1722H. View

Klein N, Edwards K, Sparks R, Dekker C . Recurrent sterile abscesses following aluminium adjuvant-containing vaccines. BMJ Case Rep. 2011; 2009. PMC: 3029045. DOI: 10.1136/bcr.09.2008.0951. View

Klein N, Fireman B, Yih W, Lewis E, Kulldorff M, Ray P . Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010; 126(1):e1-8. DOI: 10.1542/peds.2010-0665. View

10.

Camenga D, Dunne E, Desai M, Gee J, Markowitz L, Desiliva A . Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013; 40(7):534-8. DOI: 10.1097/OLQ.0b013e3182953ce0. View

11.

Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R . Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009; 170(5):650-6. PMC: 2728831. DOI: 10.1093/aje/kwp173. View

12.

Chao C, Klein N, Velicer C, Sy L, Slezak J, Takhar H . Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2011; 271(2):193-203. DOI: 10.1111/j.1365-2796.2011.02467.x. View

13.

Lowy I, Molrine D, Leav B, Blair B, Baxter R, Gerding D . Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197-205. DOI: 10.1056/NEJMoa0907635. View

14.

Rowhani-Rahbar A, Klein N, Dekker C, Edwards K, Marchant C, Vellozzi C . Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012; 31(1):271-7. DOI: 10.1016/j.vaccine.2012.07.024. View

15.

Chatterjee A, OKeefe C, Varman M, Klein N, Luber S, Tomovici A . Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: a randomized, controlled, open-label, multicenter study. Vaccine. 2012; 30(23):3360-8. DOI: 10.1016/j.vaccine.2012.03.057. View

16.

Toback S, Ambrose C, Eaton A, Hansen J, Aukes L, Lewis N . A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine. 2013; 31(14):1812-8. DOI: 10.1016/j.vaccine.2013.01.055. View

17.

Klein N, Aukes L, Lee J, Fireman B, Shapira S, Slade B . Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011; 127(5):e1139-46. DOI: 10.1542/peds.2010-3706. View

18.

Ray G, Suaya J, Baxter R . Trends and characteristics of culture-confirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J Clin Microbiol. 2012; 50(6):1950-7. PMC: 3372166. DOI: 10.1128/JCM.00134-12. View

19.

Baxter R, Toback S, Sifakis F, Hansen J, Bartlett J, Aukes L . A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine. 2012; 30(19):2989-98. DOI: 10.1016/j.vaccine.2012.02.039. View

20.

Klein N, Weston W, Kuriyakose S, Kolhe D, Howe B, Friedland L . An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2011; 30(3):668-74. DOI: 10.1016/j.vaccine.2011.10.065. View